Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Patrick Smith

Physician Assistant Wyomissing, PA Physician Assistant

NPI 1831758044 CMS profile 10712787

1802 State Hill Rd, Wyomissing, PA 19610

Open in the dashboard

General payments

$8,504

490 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Patrick Smith of Wyomissing, PA is reported in the CMS Open Payments database as having received $8,504 across 490 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,443 141
2024 General $2,148 120
2023 General $2,171 122
2022 General $1,388 85
2021 General $354 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Smith
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Patrick Smith were reported at $2,443. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Patrick Smith Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $354 $132 $37–$438 $132
2022 $1,388 $155 $48–$522 $149
2023 $2,171 $167 $52–$557 $160
2024 $2,148 $178 $55–$600 $164
2025 $2,443 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,485 140 payments
  2. Lilly USA, LLC $764 31 payments
  3. GlaxoSmithKline, LLC. $718 36 payments
  4. AstraZeneca Pharmaceuticals LP $647 36 payments
  5. Teva Pharmaceuticals USA, Inc. $520 32 payments
  6. Pfizer Inc. $459 18 payments
  7. Amgen Inc. $373 18 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $334 17 payments
  9. Novo Nordisk Inc $325 16 payments
  10. Axsome Therapeutics, Inc. $320 12 payments
  11. Other $2,559 134 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,504 490 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $632 29 payments
  2. MOUNJARO $405 18 payments
  3. QULIPTA $397 31 payments
  4. VRAYLAR Neuroscience $365 38 payments
  5. JARDIANCE $359 13 payments
  6. EVENITY $353 17 payments
  7. BREZTRI $347 17 payments
  8. VRAYLAR Neuroscience $321 44 payments
  9. UBRELVY $310 26 payments
  10. AUSTEDO $290 17 payments
  11. Other $6,429 325 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

2,363

Median for Physician Assistant: 241

Drug cost

$116,607

Median for Physician Assistant: $4,110

Branded share of claims

18.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 43 $29,217
Rybelsus Semaglutide Brand 22 $20,656
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $12,618
Eliquis Apixaban Brand 22 $10,459
Synjardy Xr Empagliflozin/Metformin Hcl Brand 12 $7,217
Gemtesa Vibegron Brand 13 $6,125
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 35 $3,891
Oxycodone Hcl Generic 73 $2,027
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 11 $1,780
Zolpidem Tartrate Generic 65 $1,570

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $160
  • Boehringer Ingelheim Pharmaceuticals, Inc. $46
$206 — —
Auvelity
  • Axsome Therapeutics, Inc. $201
$201 — —
VRAYLAR
  • AbbVie, Inc. $185
$185 — —
MOUNJARO
  • Lilly USA, LLC $112
$112 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $107
$107 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

490 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record